Skip to main content

Table 2 Dosimetric parameters

From: Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

  No. of pts. Mean ± SD Min Max
Urethra D30 [Gy] at implantation (1) 167 185.5 ± 6.7 159.8 204.5
Prostate V [cc] at implantation (2) 150 31.9 ± 11.3 12.8 63.0
Prostate V [cc] postimplant (2) 163 31.8 ± 11.1 13.8 61.4
Prostate D90 [Gy] at implantation (3) 167 185.5 ± 4.0 173.7 198.4
Prostate D90 [Gy] postimplant (3) 165 179.2 ± 16.3 118.6 210.6
Prostate V100 [%] at implantation (4) 167 99.6 ± 0.5 97.5 100
Prostate V100 [%] postimplant (4) 165 94.9 ± 3.8 80.7 100
Prostate V90.6 [%] at implantation (5) 167 99.9 ± 0.2 98.4 100
Prostate V90.6 [%] postimplant (5) 165 97.0 ± 3.8 64.5 100
Rectum V100 [cc] at implantation (6) 167 0.3 ± 0.2 0 1.2
Rectum V100 [cc] postimplant (6) 165 0.5 ± 0.6 0 3.2
  1. (1) dose to 30% of the urethra.
  2. (2) volume of the prostate.
  3. (3) dose to 90% of the prostate.
  4. (4) percentage volume receiving 100% of the prescription dose.
  5. (5) percentage volume receiving 90.6% of the prescription dose.
  6. (6) volume of the rectum receiving 100% of the prescription dose.